Nov 6, 2025 07:02AM
Nov 6, 2025 07:01AM
Aug 13, 2024 04:05PM
May 15, 2024 08:30AM
Mar 25, 2024 08:30AM
Mar 18, 2024 04:05PM
Mar 15, 2024 08:16AM Avenue Therapeutics (ATXI) Receives Positive Nasdaq Listing Determination
Mar 15, 2024 08:15AM
Mar 11, 2024 08:00AM
Feb 22, 2024 08:32AM
Feb 22, 2024 08:30AM
Jan 11, 2024 08:00AM
Jan 5, 2024 09:16AM
Jan 5, 2024 09:15AM Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds
Jan 4, 2024 08:31AM
Jan 4, 2024 08:30AM
Jan 2, 2024 08:30AM
Jan 2, 2024 08:30AM
Dec 1, 2023 08:30AM
Nov 13, 2023 04:05PM
Nov 2, 2023 03:00PM Avenue Therapeutics Announces Closing of $5.0 Million Public Offering
Oct 31, 2023 09:18AM
Oct 31, 2023 09:15AM
Aug 14, 2023 04:01PM
Aug 10, 2023 04:15PM
Aug 1, 2023 08:31AM
Aug 1, 2023 08:30AM
Jul 27, 2023 08:30AM Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
Jul 25, 2023 08:31AM
Jul 25, 2023 08:30AM
Jul 24, 2023 06:00AM
May 15, 2023 04:01PM
May 12, 2023 08:30AM
Apr 27, 2023 08:30AM
Apr 17, 2023 04:02PM Avenue Therapeutics (ATXI) Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol
Apr 17, 2023 04:01PM
Mar 30, 2023 04:10PM
Mar 30, 2023 04:01PM
Mar 8, 2023 04:04PM
Mar 8, 2023 04:01PM
Mar 2, 2023 08:01AM
Mar 2, 2023 08:00AM Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulba
Jan 31, 2023 01:09PM
Jan 27, 2023 11:59AM
Jan 27, 2023 11:58AM
Nov 10, 2022 04:10PM
Nov 8, 2022 08:30AM
Oct 11, 2022 02:15PM
Oct 7, 2022 06:09AM Avenue Therapeutics (ATXI) Prices 3.63M Share Offering at $3.30/sh
Oct 6, 2022 11:00PM

1,122,779 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All